CA2467159C - Use of therapeutic dosages for nitric oxide donors which do not significantly lower blood pressure or pulmonary artery pressure - Google Patents
Use of therapeutic dosages for nitric oxide donors which do not significantly lower blood pressure or pulmonary artery pressure Download PDFInfo
- Publication number
- CA2467159C CA2467159C CA2467159A CA2467159A CA2467159C CA 2467159 C CA2467159 C CA 2467159C CA 2467159 A CA2467159 A CA 2467159A CA 2467159 A CA2467159 A CA 2467159A CA 2467159 C CA2467159 C CA 2467159C
- Authority
- CA
- Canada
- Prior art keywords
- donor
- nitroso
- blood pressure
- disease
- pressure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000004872 arterial blood pressure Effects 0.000 title claims abstract description 76
- 239000002840 nitric oxide donor Substances 0.000 title claims abstract description 46
- 210000001147 pulmonary artery Anatomy 0.000 title claims abstract description 42
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical class O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 title abstract description 83
- 230000036772 blood pressure Effects 0.000 title abstract description 28
- 230000001225 therapeutic effect Effects 0.000 title description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 43
- 201000010099 disease Diseases 0.000 claims abstract description 39
- 210000002460 smooth muscle Anatomy 0.000 claims abstract description 19
- 230000001575 pathological effect Effects 0.000 claims abstract description 11
- 230000035755 proliferation Effects 0.000 claims abstract description 11
- 238000011282 treatment Methods 0.000 claims description 44
- 238000011321 prophylaxis Methods 0.000 claims description 38
- 230000001154 acute effect Effects 0.000 claims description 14
- XOWVFANEOZMPKG-REOHCLBHSA-N S-nitroso-L-cysteine Chemical compound OC(=O)[C@@H](N)CSN=O XOWVFANEOZMPKG-REOHCLBHSA-N 0.000 claims description 11
- 208000006673 asthma Diseases 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 9
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 9
- 208000037905 systemic hypertension Diseases 0.000 claims description 9
- NCGICGYLBXGBGN-UHFFFAOYSA-N 3-morpholin-4-yl-1-oxa-3-azonia-2-azanidacyclopent-3-en-5-imine;hydrochloride Chemical compound Cl.[N-]1OC(=N)C=[N+]1N1CCOCC1 NCGICGYLBXGBGN-UHFFFAOYSA-N 0.000 claims description 8
- 206010002383 Angina Pectoris Diseases 0.000 claims description 8
- 208000005189 Embolism Diseases 0.000 claims description 8
- 208000005872 Diffuse Esophageal Spasm Diseases 0.000 claims description 7
- QQZWEECEMNQSTG-UHFFFAOYSA-N Ethyl nitrite Chemical compound CCON=O QQZWEECEMNQSTG-UHFFFAOYSA-N 0.000 claims description 7
- 201000000660 Pyloric Stenosis Diseases 0.000 claims description 7
- 206010030184 Oesophageal spasm Diseases 0.000 claims description 6
- 206010057011 Rectal spasm Diseases 0.000 claims description 6
- 208000037803 restenosis Diseases 0.000 claims description 5
- 206010003225 Arteriospasm coronary Diseases 0.000 claims description 4
- 239000004395 L-leucine Substances 0.000 claims description 4
- 150000004007 S-nitroso compounds Chemical group 0.000 claims description 4
- 108010093594 S-nitrosoalbumin Proteins 0.000 claims description 4
- 229960003136 leucine Drugs 0.000 claims description 4
- 230000001732 thrombotic effect Effects 0.000 claims description 4
- 150000004006 C-nitroso compounds Chemical group 0.000 claims description 3
- UOHAKHBEJRPHQZ-VKHMYHEASA-N S-nitroso-L-cysteinylglycine Chemical compound O=NSC[C@H](N)C(=O)NCC(O)=O UOHAKHBEJRPHQZ-VKHMYHEASA-N 0.000 claims description 3
- 230000002496 gastric effect Effects 0.000 claims description 3
- XLFWDASMENKTKL-UHFFFAOYSA-N molsidomine Chemical compound O1C(N=C([O-])OCC)=C[N+](N2CCOCC2)=N1 XLFWDASMENKTKL-UHFFFAOYSA-N 0.000 claims description 3
- 229960004027 molsidomine Drugs 0.000 claims description 3
- 210000003205 muscle Anatomy 0.000 claims description 3
- QWPCKAAAWDCDCW-VKHMYHEASA-N (2s)-2-amino-4-nitrososulfanylbutanoic acid Chemical compound OC(=O)[C@@H](N)CCSN=O QWPCKAAAWDCDCW-VKHMYHEASA-N 0.000 claims description 2
- 150000004008 N-nitroso compounds Chemical class 0.000 claims description 2
- 150000004009 O-nitroso compounds Chemical group 0.000 claims description 2
- 125000004494 ethyl ester group Chemical group 0.000 claims description 2
- 230000002209 hydrophobic effect Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 229910052751 metal Inorganic materials 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- 150000002828 nitro derivatives Chemical class 0.000 claims description 2
- XKLJHFLUAHKGGU-UHFFFAOYSA-N nitrous amide Chemical compound ON=N XKLJHFLUAHKGGU-UHFFFAOYSA-N 0.000 claims description 2
- 229920006395 saturated elastomer Polymers 0.000 claims description 2
- 210000005166 vasculature Anatomy 0.000 claims description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-Leucine Natural products CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 1
- 235000019454 L-leucine Nutrition 0.000 claims 1
- 210000003743 erythrocyte Anatomy 0.000 abstract description 25
- 238000000034 method Methods 0.000 abstract description 19
- 208000011580 syndromic disease Diseases 0.000 abstract description 11
- 102000006240 membrane receptors Human genes 0.000 abstract description 10
- 108020004084 membrane receptors Proteins 0.000 abstract description 10
- 235000018102 proteins Nutrition 0.000 abstract description 10
- 102000004169 proteins and genes Human genes 0.000 abstract description 10
- 108090000623 proteins and genes Proteins 0.000 abstract description 10
- 150000003573 thiols Chemical class 0.000 abstract description 10
- 230000002526 effect on cardiovascular system Effects 0.000 abstract description 9
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract description 7
- 235000018417 cysteine Nutrition 0.000 abstract description 7
- 210000001367 artery Anatomy 0.000 abstract description 4
- 206010047139 Vasoconstriction Diseases 0.000 abstract description 2
- 230000025033 vasoconstriction Effects 0.000 abstract description 2
- 208000024891 symptom Diseases 0.000 description 52
- HYHSBSXUHZOYLX-WDSKDSINSA-N S-nitrosoglutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CSN=O)C(=O)NCC(O)=O HYHSBSXUHZOYLX-WDSKDSINSA-N 0.000 description 22
- 230000000694 effects Effects 0.000 description 22
- 238000001802 infusion Methods 0.000 description 16
- 102000005962 receptors Human genes 0.000 description 15
- 108020003175 receptors Proteins 0.000 description 15
- 230000004044 response Effects 0.000 description 12
- ICRHORQIUXBEPA-UHFFFAOYSA-N thionitrous acid Chemical compound SN=O ICRHORQIUXBEPA-UHFFFAOYSA-N 0.000 description 11
- 206010019280 Heart failures Diseases 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 108010001742 S-Nitrosoglutathione Proteins 0.000 description 9
- 230000008602 contraction Effects 0.000 description 9
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 9
- 229960001802 phenylephrine Drugs 0.000 description 9
- 230000001668 ameliorated effect Effects 0.000 description 8
- 230000007423 decrease Effects 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 230000000302 ischemic effect Effects 0.000 description 8
- 208000002193 Pain Diseases 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 208000010125 myocardial infarction Diseases 0.000 description 7
- 241000282472 Canis lupus familiaris Species 0.000 description 6
- 206010008479 Chest Pain Diseases 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 206010019233 Headaches Diseases 0.000 description 6
- 206010020772 Hypertension Diseases 0.000 description 6
- 208000006011 Stroke Diseases 0.000 description 6
- 238000004166 bioassay Methods 0.000 description 6
- KVGDXUBJVIZGEX-BYPYZUCNSA-N ethyl (2r)-2-amino-3-nitrososulfanylpropanoate Chemical compound CCOC(=O)[C@@H](N)CSN=O KVGDXUBJVIZGEX-BYPYZUCNSA-N 0.000 description 6
- 238000011010 flushing procedure Methods 0.000 description 6
- 231100000869 headache Toxicity 0.000 description 6
- 238000001990 intravenous administration Methods 0.000 description 6
- 208000028867 ischemia Diseases 0.000 description 6
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 230000006442 vascular tone Effects 0.000 description 6
- 208000019901 Anxiety disease Diseases 0.000 description 5
- 201000001320 Atherosclerosis Diseases 0.000 description 5
- 206010005746 Blood pressure fluctuation Diseases 0.000 description 5
- 208000000059 Dyspnea Diseases 0.000 description 5
- 206010013975 Dyspnoeas Diseases 0.000 description 5
- 108010068048 S-nitrosohemoglobin Proteins 0.000 description 5
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 5
- 229960004373 acetylcholine Drugs 0.000 description 5
- 230000036506 anxiety Effects 0.000 description 5
- 210000000709 aorta Anatomy 0.000 description 5
- 210000004204 blood vessel Anatomy 0.000 description 5
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 5
- 229910052753 mercury Inorganic materials 0.000 description 5
- 230000003134 recirculating effect Effects 0.000 description 5
- 230000002040 relaxant effect Effects 0.000 description 5
- 208000013220 shortness of breath Diseases 0.000 description 5
- 230000009885 systemic effect Effects 0.000 description 5
- 108060003345 Adrenergic Receptor Proteins 0.000 description 4
- 102000017910 Adrenergic receptor Human genes 0.000 description 4
- 108091006146 Channels Proteins 0.000 description 4
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 229960004308 acetylcysteine Drugs 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 208000029078 coronary artery disease Diseases 0.000 description 4
- 230000006735 deficit Effects 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 238000001361 intraarterial administration Methods 0.000 description 4
- 230000000284 resting effect Effects 0.000 description 4
- 230000035488 systolic blood pressure Effects 0.000 description 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 102000029797 Prion Human genes 0.000 description 3
- 108091000054 Prion Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 239000000048 adrenergic agonist Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 229940076279 serotonin Drugs 0.000 description 3
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 2
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 102000003951 Erythropoietin Human genes 0.000 description 2
- 108090000394 Erythropoietin Proteins 0.000 description 2
- 208000004248 Familial Primary Pulmonary Hypertension Diseases 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 206010022562 Intermittent claudication Diseases 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 2
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000009668 Neurobehavioral Manifestations Diseases 0.000 description 2
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 2
- 239000000006 Nitroglycerin Substances 0.000 description 2
- 208000031481 Pathologic Constriction Diseases 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 206010036772 Proctalgia Diseases 0.000 description 2
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 208000032109 Transient ischaemic attack Diseases 0.000 description 2
- 208000006906 Vascular Ring Diseases 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 208000024980 claudication Diseases 0.000 description 2
- 230000001149 cognitive effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000002517 constrictor effect Effects 0.000 description 2
- 229940105423 erythropoietin Drugs 0.000 description 2
- 230000005713 exacerbation Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 229960003711 glyceryl trinitrate Drugs 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 210000005246 left atrium Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 238000011587 new zealand white rabbit Methods 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
- 201000008312 primary pulmonary hypertension Diseases 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 102000016914 ras Proteins Human genes 0.000 description 2
- 108010014186 ras Proteins Proteins 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 201000010875 transient cerebral ischemia Diseases 0.000 description 2
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 206010002388 Angina unstable Diseases 0.000 description 1
- 208000037874 Asthma exacerbation Diseases 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 241001631457 Cannula Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 206010014498 Embolic stroke Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010020844 Hyperthermia malignant Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 102000002397 Kinins Human genes 0.000 description 1
- 108010093008 Kinins Proteins 0.000 description 1
- 239000012839 Krebs-Henseleit buffer Substances 0.000 description 1
- 208000005230 Leg Ulcer Diseases 0.000 description 1
- 208000018717 Malignant hyperthermia of anesthesia Diseases 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 208000001089 Multiple system atrophy Diseases 0.000 description 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
- 206010049816 Muscle tightness Diseases 0.000 description 1
- 206010030180 Oesophageal pain Diseases 0.000 description 1
- 206010031127 Orthostatic hypotension Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 201000001068 Prinzmetal angina Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 102000001424 Ryanodine receptors Human genes 0.000 description 1
- ZIIQCSMRQKCOCT-YFKPBYRVSA-N S-nitroso-N-acetyl-D-penicillamine Chemical compound CC(=O)N[C@@H](C(O)=O)C(C)(C)SN=O ZIIQCSMRQKCOCT-YFKPBYRVSA-N 0.000 description 1
- 230000006295 S-nitrosylation Effects 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 206010043395 Thalassaemia sickle cell Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 206010047163 Vasospasm Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- MKYGMVOKULQJBW-UHFFFAOYSA-N [3-(nitrooxymethyl)phenyl] 2-hydroxybenzoate Chemical compound OC1=CC=CC=C1C(=O)OC1=CC=CC(CO[N+]([O-])=O)=C1 MKYGMVOKULQJBW-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 210000005091 airway smooth muscle Anatomy 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 239000002160 alpha blocker Substances 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 230000000489 anti-atherogenic effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 210000002302 brachial artery Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000007681 cardiovascular toxicity Effects 0.000 description 1
- 231100000060 cardiovascular toxicity Toxicity 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000001595 contractor effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- XEYBHCRIKKKOSS-UHFFFAOYSA-N disodium;azanylidyneoxidanium;iron(2+);pentacyanide Chemical compound [Na+].[Na+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].[O+]#N XEYBHCRIKKKOSS-UHFFFAOYSA-N 0.000 description 1
- -1 e.g. Proteins 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 230000009986 erectile function Effects 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 208000018875 hypoxemia Diseases 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 206010023497 kuru Diseases 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 201000007004 malignant hyperthermia Diseases 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 229940111688 monobasic potassium phosphate Drugs 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 125000000018 nitroso group Chemical group N(=O)* 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000008695 pulmonary vasoconstriction Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000004648 relaxation of smooth muscle Effects 0.000 description 1
- 108091052345 ryanodine receptor (TC 1.A.3.1) family Proteins 0.000 description 1
- 239000000952 serotonin receptor agonist Substances 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229940083618 sodium nitroprusside Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000013125 spirometry Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 210000000779 thoracic wall Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000001196 vasorelaxation Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000001720 vestibular Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/986,807 US6472390B1 (en) | 2001-11-13 | 2001-11-13 | Use of therapeutic dosages for nitric oxide donors which do not significantly lower blood pressure or pulmonary artery pressure |
| US09/986,807 | 2001-11-13 | ||
| PCT/US2002/025937 WO2003041713A1 (en) | 2001-11-13 | 2002-08-26 | Use of therapeutic dosages for nitric oxide donors which do not significantly lower blood pressure or pulmonary artery pressure |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2467159A1 CA2467159A1 (en) | 2003-05-22 |
| CA2467159C true CA2467159C (en) | 2012-03-13 |
Family
ID=25532762
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2467159A Expired - Fee Related CA2467159C (en) | 2001-11-13 | 2002-08-26 | Use of therapeutic dosages for nitric oxide donors which do not significantly lower blood pressure or pulmonary artery pressure |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US6472390B1 (enExample) |
| EP (1) | EP1458397A4 (enExample) |
| JP (2) | JP5259038B2 (enExample) |
| AU (1) | AU2002313758B2 (enExample) |
| CA (1) | CA2467159C (enExample) |
| WO (1) | WO2003041713A1 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2794647A1 (fr) * | 1999-06-11 | 2000-12-15 | Centre Nat Rech Scient | Compositions pharmaceutique comprenant du no ou au moins un compose capable de liberer ou d'induire la formation de no dans les cellules |
| US7516742B2 (en) | 1999-11-24 | 2009-04-14 | Cardinal Health 207, Inc. | Method and apparatus for delivery of inhaled nitric oxide to spontaneous-breathing and mechanically-ventilated patients with intermittent dosing |
| US7122018B2 (en) | 2000-12-26 | 2006-10-17 | Sensormedics Corporation | Device and method for treatment of wounds with nitric oxide |
| US6432077B1 (en) | 2000-12-26 | 2002-08-13 | Sensormedics Corporation | Device and method for treatment of surface infections with nitric oxide |
| US20040225275A1 (en) * | 2001-08-02 | 2004-11-11 | Reynolds James Dixon | Fetal physiology during maternal surgery or diagnosis |
| US6676855B2 (en) * | 2001-08-02 | 2004-01-13 | Duke University | Use of a blood-flow decrease preventing agent in conjunction with insufflating gas |
| GB0125222D0 (en) * | 2001-10-19 | 2001-12-12 | Barts & London Nhs Trust | Composition for the treatment of microbial infections |
| US6627602B2 (en) * | 2001-11-13 | 2003-09-30 | Duke University | Preventing desensitization of receptors |
| US20040110691A1 (en) * | 2001-11-13 | 2004-06-10 | Stamler Jonathan S. | Thiol reactive agents as a therapeutic modality |
| EP1514103A4 (en) * | 2002-05-29 | 2006-05-24 | Univ Duke | MEASUREMENT OF NITROGEN MONOXIDE IN HEMOTOXIC GASES, AND TREATMENT BASED ON THIS MEASURE |
| US7531133B2 (en) | 2002-09-10 | 2009-05-12 | Pulmonox Technologies Corporation | Use of nitric oxide gas in an extracorporeal circuitry to treat blood plasma |
| WO2005004884A2 (en) * | 2003-07-09 | 2005-01-20 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Use of nitrite salts for the treatment of cardiovascular conditions |
| CA2542426A1 (en) * | 2003-10-22 | 2005-05-06 | Fred Hutchinson Cancer Research Center | Methods, compositions and devices for inducing stasis in cells |
| US20070270350A1 (en) * | 2003-12-23 | 2007-11-22 | Musc Foundation For Research Development | Methods and Compositions for the Prevention and Treatment of Inflammatory Diseases or Conditions |
| WO2005079782A1 (en) * | 2004-02-17 | 2005-09-01 | Thiolex Development Corp. | N-acetylcysteine compositions and methods for the treatment and prevention of endothelial dysfunction |
| CA2561141A1 (en) * | 2004-03-31 | 2005-11-17 | Nitromed, Inc. | Methods for treating blood disorders with nitric oxide donor compounds |
| FR2868314B1 (fr) * | 2004-04-05 | 2008-10-24 | Therabel Pharmaceuticals Ltd | Nouvelle utilisation therapeutique de la molsidomine et de ses sels pharmaceutiquement acceptables |
| MXPA06013111A (es) | 2004-05-11 | 2007-05-23 | Sensormedics Corp | Dosificacion intermitente de gas de oxido nitrico. |
| US8518457B2 (en) | 2004-05-11 | 2013-08-27 | Pulmonox Technologies Corporation | Use of inhaled gaseous nitric oxide as a mucolytic agent or expectorant |
| US7362274B1 (en) * | 2004-07-09 | 2008-04-22 | Huan-Cheng Lien | Coupled feed-in butterfly shaped left/right hand circularly polarized microstrip antenna |
| US8557300B2 (en) * | 2005-05-19 | 2013-10-15 | University Of Cincinnati | Methods for treating bacterial respiratory tract infections in an individual using acidified nitrite |
| EP2669269B1 (en) | 2005-05-27 | 2019-05-22 | The University of North Carolina At Chapel Hill | Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications |
| AU2007217980A1 (en) * | 2006-02-17 | 2007-08-30 | Nitromed, Inc. | Methods using hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate |
| WO2007103534A2 (en) * | 2006-03-07 | 2007-09-13 | Nitrox, Llc | Ethyl nitrite as a gastrointestinal smooth muscle relaxant and diagnostic and therapeutic uses thereof |
| WO2007146311A2 (en) * | 2006-06-12 | 2007-12-21 | N30 Pharmaceuticals, Llc | Compositions and methods for protecting newborn lung development with ethyl nitrite |
| US8079998B2 (en) | 2006-10-20 | 2011-12-20 | Pulmonox Technologies Corporation | Methods and devices for the delivery of therapeutic gases including nitric oxide |
| US20110003012A1 (en) * | 2007-09-10 | 2011-01-06 | Duke University | Treating patients with subarachnoid hemorrhage |
| US20090196930A1 (en) * | 2007-12-27 | 2009-08-06 | Aires Pharmaceuticals, Inc. | Aerosolized nitrite and nitric oxide -donating compounds and uses thereof |
| US20110104308A1 (en) * | 2008-05-09 | 2011-05-05 | Duke University | Treatment For Diseases Relying On Discovery That Thioredoxin Mediates Nitric Oxide |
| WO2011022652A1 (en) | 2009-08-21 | 2011-02-24 | Novan, Inc. | Topical gels |
| EP2467173B8 (en) | 2009-08-21 | 2019-06-19 | Novan, Inc. | Wound dressings, methods of using the same and methods of forming the same |
| US8591876B2 (en) | 2010-12-15 | 2013-11-26 | Novan, Inc. | Methods of decreasing sebum production in the skin |
| WO2012118819A2 (en) | 2011-02-28 | 2012-09-07 | Novan, Inc. | Nitric oxide-releasing s-nitrosothiol-modified silica particles and methods of making the same |
| JP6251849B2 (ja) * | 2015-10-13 | 2017-12-20 | 学校法人慶應義塾 | 椎間板変性症、腰痛改善を処置するための医薬組成物、及び治療薬のスクリーニング方法 |
| WO2019073045A1 (en) | 2017-10-12 | 2019-04-18 | Bdd Berolina Drug Development Gmbh | USE OF DONORS OF NO |
| US20240226140A1 (en) * | 2023-01-09 | 2024-07-11 | Azulent, Llc | Nitric oxide and molecular hydrogen generating compositions |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4900719A (en) * | 1988-08-05 | 1990-02-13 | The Ohio State University | Nitrosothiols as hypotensive agents |
| US5208233A (en) * | 1989-09-15 | 1993-05-04 | The United States Of America As Represented By The Department Of Health And Human Services | Anti-hypertensive compositions of secondary amine-nitric oxide adducts and use thereof |
| DE69127756T2 (de) * | 1990-12-05 | 1998-02-05 | The General Hospital Corp., Charlestown, Mass. | Verwendung von no zur behandlung oder prävention der bronchokonstriktion |
| NZ249176A (en) * | 1992-02-07 | 1996-11-26 | Vasogen Inc | Method of increasing concentration of nitric oxide in blood using ozone and uv radiation |
| US5385940A (en) * | 1992-11-05 | 1995-01-31 | The General Hospital Corporation | Treatment of stroke with nitric-oxide releasing compounds |
| US5861168A (en) * | 1993-06-11 | 1999-01-19 | The Board Of Trustees Of The Leland Stanford Junior University | Intramural delivery of nitric oxide enhancer for inhibiting lesion formation after vascular injury |
| US5891459A (en) * | 1993-06-11 | 1999-04-06 | The Board Of Trustees Of The Leland Stanford Junior University | Enhancement of vascular function by modulation of endogenous nitric oxide production or activity |
| US6063407A (en) * | 1995-02-16 | 2000-05-16 | The General Hospital Corporation | Treatment of vascular thrombosis and restenosis with inhaled nitric oxide |
| US5869539A (en) * | 1996-04-17 | 1999-02-09 | Board Of Regents, The University Of Texas System | Emulsions of perfluoro compounds as solvents for nitric oxide (NO) |
| EP0951292B1 (en) * | 1996-09-27 | 2007-04-04 | The Trustees of Columbia University in the City of New York | Treating an ischemic disorder and improving stroke outcome |
| FR2757864B1 (fr) * | 1996-12-30 | 1999-03-19 | Centre Nat Rech Scient | Anticorps reconnaissant specifiquement une proteine nitrosylee, leur procede de preparation, leur utilisation therapeutique et diagnostique |
| AU9596698A (en) * | 1997-10-15 | 1999-05-03 | Thomas Jefferson University | Nitric oxide donor compositions, methods, apparatus, and kits for preventing or alleviating vasoconstriction or vasospasm in a mammal |
| JPH11217330A (ja) * | 1998-01-30 | 1999-08-10 | Sumitomo Pharmaceut Co Ltd | 神経栄養因子分泌促進剤 |
| US6265420B1 (en) * | 1998-06-23 | 2001-07-24 | Medinox, Inc. | Use of nitric oxide scavengers to treat side effects caused by therapeutic administration of sources of nitric oxide |
| US6007824A (en) * | 1998-07-09 | 1999-12-28 | Duckett; Melvin J. | Natural composition and method for the treatment of sexual dysfunction |
| US6314956B1 (en) * | 1999-09-08 | 2001-11-13 | Duke University | Pulmonary delivery of NO group-containing compound in gas form to treat respiratory, cardiac and blood disorders |
-
2001
- 2001-11-13 US US09/986,807 patent/US6472390B1/en not_active Expired - Lifetime
-
2002
- 2002-08-26 EP EP02753472A patent/EP1458397A4/en not_active Withdrawn
- 2002-08-26 JP JP2003543600A patent/JP5259038B2/ja not_active Expired - Fee Related
- 2002-08-26 CA CA2467159A patent/CA2467159C/en not_active Expired - Fee Related
- 2002-08-26 WO PCT/US2002/025937 patent/WO2003041713A1/en not_active Ceased
- 2002-08-26 AU AU2002313758A patent/AU2002313758B2/en not_active Ceased
-
2009
- 2009-05-07 JP JP2009113076A patent/JP2009167223A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| JP5259038B2 (ja) | 2013-08-07 |
| US6472390B1 (en) | 2002-10-29 |
| AU2002313758B2 (en) | 2006-06-22 |
| EP1458397A1 (en) | 2004-09-22 |
| WO2003041713A1 (en) | 2003-05-22 |
| EP1458397A4 (en) | 2007-03-07 |
| JP2005509004A (ja) | 2005-04-07 |
| CA2467159A1 (en) | 2003-05-22 |
| JP2009167223A (ja) | 2009-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6472390B1 (en) | Use of therapeutic dosages for nitric oxide donors which do not significantly lower blood pressure or pulmonary artery pressure | |
| AU2002313758A1 (en) | Use of therapeutic dosages for nitric oxide donors which do not significantly lower blood pressure or pulmonary artery pressure | |
| Fang et al. | The role of NO in COVID-19 and potential therapeutic strategies | |
| JP5004391B2 (ja) | Ｎｏ基化合物で心肺疾病を処置する方法 | |
| Cooke | NO and angiogenesis | |
| US8927030B2 (en) | Use of nitrite salts for the treatment of cardiovascular conditions | |
| Troncy et al. | Extra-pulmonary effects of inhaled nitric oxide in swine with and without phenylephrine | |
| JP3779726B2 (ja) | 薬剤組成物を製造するためのガス状酸化窒素の使用法 | |
| Lange et al. | Role of nitric oxide in shock: the large animal perspective | |
| Khan et al. | Novel astaxanthin prodrug (CDX-085) attenuates thrombosis in a mouse model | |
| Gille et al. | Safety of resuscitation with Ringer's acetate solution in severe burn (VolTRAB)—an observational trial | |
| CN1481256A (zh) | 一氧化氮的吸入 | |
| Hirota | Hypoxia-dependent signaling in perioperative and critical care medicine | |
| JP2006503901A (ja) | レセプターの脱感作の予防 | |
| JP2020525511A (ja) | 低濃度のキセノンおよびアルゴンを含有するガス混合物は血栓溶解剤の触媒活性を阻害することなく神経保護を提供する | |
| Hong et al. | Perioperative assessment of terlipressin infusion during living donor liver transplantation | |
| US8974836B2 (en) | Angiogenesis regulating composition and method for regulating angiogenesis | |
| Jiang et al. | SS-31 improves post-cardiac arrest brain injury by inhibiting microglial ferroptosis and polarization | |
| RU2409373C2 (ru) | Применение солей лития для лечения острой почечной недостаточности | |
| CN113116885A (zh) | 一种茶多酚类化合物在制备抗血栓药物中的应用 | |
| RU2789253C1 (ru) | Способ реабилитации пациентов, перенесших COVID-19 | |
| JP2014507468A (ja) | 哺乳類の正常血糖を維持するための方法 | |
| Drachuk et al. | CHANGES IN FIBRINO-AND PROTEOLYTIC ACTIVITY IN RATS KIDNEYS UNDER THE INFLUENCE OF EXOGENOUS GLUTATHIONE ON THE BACKGROUND OF RHABDOMYOLYSIS-INDUCED ACUTE KIDNEY INJURY | |
| Mazmanian et al. | Pressor responses of rat isolated tail arteries to contractile stimulation after methylene blue treatment: effect of adventitial versus intimal entry | |
| KR20260018831A (ko) | 혈전색전증 치료에 사용하기 위한 모노- 및 비스-니트로실화 프로판디올 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20170828 |